<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00912184</url>
  </required_header>
  <id_info>
    <org_study_id>High cut-off trial</org_study_id>
    <nct_id>NCT00912184</nct_id>
  </id_info>
  <brief_title>Study Comparing High Cut-off Haemofiltration With Standard Haemofiltration in Acute Renal Failure</brief_title>
  <official_title>Pilot Randomised Controlled Study Comparing The Effect of High Cut-off Point Haemofiltration With Standard Haemofiltration In Patients With Acute Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austin Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Austin Health</source>
  <brief_summary>
    <textblock>
      This trial aims to study the effect of combining continuous and a new polyamide membrane with
      larger pores in the treatment of critically ill patients with acute renal failure and low
      blood pressure (shock) requiring noradrenaline. The investigators wish to compare the
      clinical effect of this new therapy to that of haemofiltration with a standard membrane.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During acute renal failure, small and middle molecular-weight toxins accumulate. These
      molecules are difficult to remove by standard haemofiltration. Accordingly, they accumulate
      and contribute to morbidity in long-term dialysis patients. Molecules such as cytokines have
      been shown to play a central pathogenic role in critical illness. In critically ill acute
      renal failure patients, they accumulate in serum and likely contribute to much morbidity
      (fever, low blood pressure, myocardial dysfunction, renal failure itself etc.) Therefore, the
      removal of cytokines appears desirable. Although different approaches have been undertaken,
      all have had limited success due to complexity, limited efficacy or uncertain clinical
      response [10-15].

      It is possible that in using a different and more porous membrane, the removal of cytokines
      would be much more efficient and that clinical benefits of blood purification would,
      therefore, be greater.

      A membrane of this kind is now available. It is a modification (moderate increase in pore
      size) of another standard material called polyamide, which has already been used in millions
      of people for dialysis and haemofiltration. The increased pore size of these new membranes is
      directed at a more effective removal of middle molecular-weight toxins such as cytokines.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure for this study is noradrenaline free time in the first week after randomization</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in the levels of each of three key cytokines; IL-1, IL-6 and IL-10</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Kidney Failure, Acute</condition>
  <condition>Shock</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CVVH with high cut-off polyamide membrane (P2SH) using standard continuous veno-venous hemofiltration (CVVH) settings</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CVVH using standard high flux membrane with standard CVVH settings</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard polyamide high flux membrane</intervention_name>
    <description>Standard haemofiltration; CVVH; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hr, anticoagulation as clinically indicated, bicarbonate buffered replacement fluid</description>
    <arm_group_label>2</arm_group_label>
    <other_name>High flux membrane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High cut-off (super high flux) polyamide membrane</intervention_name>
    <description>CVVH with standard haemofiltration settings; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hour, anticoagulation as clinically indicated, bicarbonate-buffered replacement fluid</description>
    <arm_group_label>1</arm_group_label>
    <other_name>P2SH</other_name>
    <other_name>Super high flux membrane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The treating clinician believes that the patient requires haemofiltration for acute
             renal failure

          -  The patient is on noradrenaline infusion for haemodynamic support

          -  The patient was commenced on noradrenaline or haemofiltration within the last 12 hours

          -  The clinician is uncertain about the balance of benefits and risks likely to be
             conferred by treatment with different membranes

          -  The treating clinicians anticipate treating the patient with haemofiltration for at
             least 72 hours

          -  Informed consent has been obtained

          -  The patient fulfils ONE of the following clinical criteria for initiating
             haemofiltration:

          -  Oliguria (urine output &lt; 100 ml/6 hr) that has been unresponsive to fluid
             resuscitation measures.

          -  Hyperkalemia ([K+] &gt; 6.5 mmol/L)

          -  Severe acidemia (pH &lt; 7.2)

          -  Urea &gt; 25 mmol/liter

          -  Creatinine &gt; 300 mmol/L

          -  Clinically significant organ oedema in the setting of ARF (e.g., lung)

        Exclusion Criteria:

          -  Patient age is &lt; 18 years

          -  Death is imminent (&lt; 24 hours)

          -  There is a strong likelihood that the study treatment would not be continued in
             accordance with the study protocol

          -  The patient has been treated with haemofiltration or other dialysis previously during
             the same hospital admission

          -  The patient was on maintenance dialysis prior to the current hospitalisation

          -  Any other major illness that, in the investigator's judgment, will substantially
             increase the risk associated with the subject's participation in this study

          -  The patient is pregnant or is breastfeeding

          -  The patient has previously been enrolled in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafidah Atan, MBBS, FANZCA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austin Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V, Cardona X, Inguaggiato P, Pilotto L, d'Intini V, Bellomo R. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs. 2003 Sep;27(9):792-801. Review.</citation>
    <PMID>12940901</PMID>
  </reference>
  <reference>
    <citation>Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med. 2001 Jul;29(7 Suppl):S99-106. Review.</citation>
    <PMID>11445742</PMID>
  </reference>
  <reference>
    <citation>Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993 May 20;328(20):1471-7. Review.</citation>
    <PMID>8479467</PMID>
  </reference>
  <reference>
    <citation>Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med. 1996 Jul;24(7):1125-8.</citation>
    <PMID>8674323</PMID>
  </reference>
  <reference>
    <citation>Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest. 1993 Feb;103(2):565-75.</citation>
    <PMID>8432155</PMID>
  </reference>
  <reference>
    <citation>Hack CE, Aarden LA, Thijs LG. Role of cytokines in sepsis. Adv Immunol. 1997;66:101-95. Review.</citation>
    <PMID>9328641</PMID>
  </reference>
  <reference>
    <citation>Dinarello CA. Proinflammatory cytokines. Chest. 2000 Aug;118(2):503-8. Review.</citation>
    <PMID>10936147</PMID>
  </reference>
  <reference>
    <citation>Glauser MP. The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock. Drugs. 1996;52 Suppl 2:9-17. Review.</citation>
    <PMID>8869831</PMID>
  </reference>
  <reference>
    <citation>Bellomo R, Tipping P, Boyce N. Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med. 1993 Apr;21(4):522-6.</citation>
    <PMID>8472571</PMID>
  </reference>
  <reference>
    <citation>Bellomo R. Continuous hemofiltration as blood purification in sepsis. New Horiz. 1995 Nov;3(4):732-7. Review.</citation>
    <PMID>8574604</PMID>
  </reference>
  <reference>
    <citation>De Vriese AS, Colardyn FA, Philipp√© JJ, Vanholder RC, De Sutter JH, Lameire NH. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol. 1999 Apr;10(4):846-53.</citation>
    <PMID>10203370</PMID>
  </reference>
  <reference>
    <citation>Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D. Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Kidney Int. 1995 Nov;48(5):1563-70.</citation>
    <PMID>8544415</PMID>
  </reference>
  <reference>
    <citation>Gasche Y, Pascual M, Suter PM, Favre H, Chevrolet JC, Schifferli JA. Complement depletion during haemofiltration with polyacrilonitrile membranes. Nephrol Dial Transplant. 1996 Jan;11(1):117-9.</citation>
    <PMID>8649617</PMID>
  </reference>
  <reference>
    <citation>Kellum JA, Johnson JP, Kramer D, Palevsky P, Brady JJ, Pinsky MR. Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Crit Care Med. 1998 Dec;26(12):1995-2000.</citation>
    <PMID>9875910</PMID>
  </reference>
  <reference>
    <citation>Cole L, Bellomo R, Hart G, Journois D, Davenport P, Tipping P, Ronco C. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med. 2002 Jan;30(1):100-6.</citation>
    <PMID>11902250</PMID>
  </reference>
  <reference>
    <citation>Lee WC, Uchino S, Fealy N, Baldwin I, Panagiotopoulos S, Goehl H, Morgera S, Neumayer HH, Bellomo R. Super high flux hemodialysis at high dialysate flows: an ex vivo assessment. Int J Artif Organs. 2004 Jan;27(1):24-8.</citation>
    <PMID>14984180</PMID>
  </reference>
  <reference>
    <citation>Uchino S, Bellomo R, Morimatsu H, Goldsmith D, Davenport P, Cole L, Baldwin I, Panagiotopoulos S, Tipping P, Morgera S, Neumayer HH, Goehl H. Cytokine dialysis: an ex vivo study. ASAIO J. 2002 Nov-Dec;48(6):650-3.</citation>
    <PMID>12455777</PMID>
  </reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2009</study_first_submitted>
  <study_first_submitted_qc>June 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2009</study_first_posted>
  <last_update_submitted>January 26, 2012</last_update_submitted>
  <last_update_submitted_qc>January 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Austin Health</investigator_affiliation>
    <investigator_full_name>Rafidah Atan</investigator_full_name>
    <investigator_title>PhD student</investigator_title>
  </responsible_party>
  <keyword>Kidney failure, acute</keyword>
  <keyword>Shock</keyword>
  <keyword>Toxins, biological</keyword>
  <keyword>Hemofiltration</keyword>
  <keyword>High cut off/super high flux membranes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

